Laurus Labs Limited (NSE:LAURUSLABS)
1,542.30
+14.30 (0.94%)
Jul 3, 2026, 3:29 PM IST
Laurus Labs Revenue
In the fiscal year ending March 31, 2026, Laurus Labs had annual revenue of 68.13B INR with 22.67% growth. Laurus Labs had revenue of 18.12B in the quarter ending March 31, 2026, with 5.31% growth.
Revenue
68.13B
Revenue Growth
+22.67%
P/S Ratio
12.22
Revenue / Employee
9.65M
Employees
7,059
Market Cap
832.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 68.13B | 12.59B | 22.67% |
| Mar 31, 2025 | 55.54B | 5.13B | 10.18% |
| Mar 31, 2024 | 50.41B | -10.00B | -16.55% |
| Mar 31, 2023 | 60.41B | 11.05B | 22.39% |
| Mar 31, 2022 | 49.36B | 1.22B | 2.54% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 336.53B |
| Cipla | 278.28B |
| Zydus Lifesciences | 271.48B |
| Glenmark Pharmaceuticals | 169.83B |
| Alkem Laboratories | 147.12B |
| Mankind Pharma | 142.78B |
| Divi's Laboratories | 105.60B |
| Ipca Laboratories | 96.46B |
Laurus Labs News
- 3 days ago - Laurus Labs appoints Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as independent directors - Business Upturn
- 3 days ago - Laurus Labs Transcript: AGM 2026 - Transcripts
- 6 days ago - Nifty rebalancing today: MCX, NTPC, Laurus Labs among top inflow beneficiaries; Bharti Airtel, Eicher Motors face highest outflows - Business Upturn
- 27 days ago - Laurus Labs reports 62.14% export contribution to total turnover in FY 2025-26 - Business Upturn
- 4 weeks ago - Laurus Labs allots equity shares worth over Rs 12 crore under ESOP schemes - Business Upturn
- 6 weeks ago - Laurus Labs included in Dow Jones Best-in-Class indices for ESG performance - Business Upturn
- 2 months ago - Laurus Labs Transcript: Q4 25/26 - Transcripts
- 2 months ago - Laurus Labs Quarterly report: Q4 2026 - Filings